Is Legend Biotech (LEGN) One of the Overlooked Growth Stocks to Buy Now?

Legend Biotech Corporation (NASDAQ:LEGN) is one of the 10 Overlooked Growth Stocks to Buy Now.

Legend Biotech Corporation (NASDAQ:LEGN) is one of the overlooked growth stocks to buy now. Earlier on March 10, Legend Biotech reported financial results for the full year 2025, headlined by the continued commercial success of its multiple myeloma therapy, CARVYKTI. The treatment generated net trade sales of ~$555 million in Q4 and $1.9 billion for 2025, leading the CARVYKTI franchise to achieve full-year profitability.

This growth was supported by a significant increase in collaboration revenue, which rose to $277.6 million in the final quarter. The company reached a major clinical milestone in 2025, surpassing 10,000 patients treated with CARVYKT across clinical and commercial settings. To support this rising demand, Legend Biotech expanded its Raritan manufacturing facility, making it the largest cell therapy production site in the US with the capacity to treat 10,000 patients annually.

Is Legend Biotech (LEGN) One of the Overlooked Growth Stocks to Buy Now?

Mila Supinskaya Glashchenko/Shutterstock.com

The therapy’s global footprint also grew to 294 sites across 14 markets, with a focus on increasing adoption within the US community and outpatient settings. New data presented at major medical meetings continued to reinforce the durable outcomes associated with using the therapy in earlier lines of treatment. Beyond its flagship product, Legend Biotech Corporation (NASDAQ:LEGN) advanced its early-stage pipeline and research infrastructure. The company opened a new 31,000-square-foot R&D facility in Philadelphia and achieved first-patient dosing for its in vivo pipeline candidates.

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms.

While we acknowledge the risk and potential of LEGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LEGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.